Jesus Berdeja | EHA 2018 | The CRB-401 phase I bb2121 CAR T-cell study

23rd Congress of European Hematology Association, 14-17 June 2018, Stockholm, Sweden

Jesus Berdeja
Sarah Cannon Research Institute, Nashville, US

Interview topic: Summary of results from the CRB-401 phase I bb2121 CAR-T cell study

The CRB-401 phase I bb2121 CAR T-cell study

ASCO 2018 | Updated results from the CRB-401 phase I study of bb2121 CAR T-cells

Noopur Raje presented an update of the bb2121 phase I dose escalation and expansion study of RRMM patients

ASCO 2018 | Updated results from the CRB-401 phase I study of bb2121 CAR T-cells

Noopur Raje presented an update of the bb2121 phase I dose escalation and expansion study of RRMM patients

ASH 2017 | BCMA as a target for MM

A summary of ASH abstracts with the common theme of targeting BCMA

ASH 2017 | BCMA as a target for MM

A summary of ASH abstracts with the common theme of targeting BCMA

Subscribe to get the best content related to multiple myeloma delivered to your inbox every month

First Name

Last Name

I agree to the Multiple Myeloma Hub Terms & Conditions